INSM: I think you have missed an important point... INSM lost. It is difficult to "dominate" any market when you are no longer involved in said market. As for whether or not they have a superior product, well, it is all a matter of degree and is also quite moot at this juncture.
(Having 130 or 150 paying patients is also quite unimpressive).
It is time for some of you to get over it, imo. I would not be invested in either company.
Market Data 
Markets 
AI
